Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532324 | 0.83 | KMT2A (0.36) | — | |
| SCHEMBL290041 | 0.83 | — | — | |
| SCHEMBL190709 | 0.82 | NUDT1 (0.32) | — | |
| SCHEMBL583753 | 0.81 | DGAT1 (0.33) | — | |
| SCHEMBL2346145 | 0.81 | CYP3A4 (0.30) | — | |
| SCHEMBL2722855 | 0.81 | — | — | |
| SCHEMBL1502522 | 0.80 | NNMT (0.37) | KDM4ENNMT | |
| SCHEMBL16734834 | 0.79 | TRPV1 (0.33) | — | |
| SCHEMBL15059078 | 0.79 | — | — | |
| SCHEMBL15201656 | 0.79 | TRPV4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154011-A | Chemical pesticide composition and preparation method thereof | 潍坊华诺生物科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120001342-A | PH responsive magnetic grading porous MOFs composite material and preparation method and application thereof | 德宏师范高等专科学校 | 2025-05-16 | — | — | CN | claimed |
| CN-119241426-A | Pyrenyl Schiff base fluorescent derivative, fluorescent probe, preparation method of pyrenyl Schiff base fluorescent derivative and application of pyrenyl Schiff base fluorescent derivative and fluorescent probe in biological imaging | 河北师范大学 | 2025-01-03 | — | — | CN | claimed |
| CN-113501819-B | Pyridoimidazole substituted quinazolinone derivative, and synthetic method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2024-02-02 | — | — | CN | claimed |
| CN-113136020-B | Water-based polyurethane polymer and preparation method thereof, single-component water-based polyurethane waterproof coating and preparation method and application thereof | 万华化学集团股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113136020-A | Water-based polyurethane polymer and preparation method thereof, single-component water-based polyurethane waterproof coating and preparation method and application thereof | 万华化学集团股份有限公司 | 2021-07-20 | — | — | CN | claimed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-12492194-B2 | HPK1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-09 | — | — | US | disclosed |
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-116239580-B | Triazine compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2025-05-23 | — | — | CN | disclosed |
| EP-3947366-B1 | HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008039520-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | disclosed |
| WO-2007137107-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| WO-2007089904-A2 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254926-A1 | Pyridylphenyl compounds for inflammation and immune-related uses | CCR1, CXCR3, NLRP1 | KDM4E 1148/4885HSD17B10 3818/4885NOS3 1040/4885 |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NOD2, RORC, NLRP3 | KDM4E 1715/4885HSD17B10 1668/4885NOS3 712/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | KDM4E 4033/4885HSD17B10 1962/4885NOS3 2381/4885 |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, DLAT | KDM4E 2852/4885HSD17B10 327/4885NOS3 3614/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | KDM4E 2139/4885HSD17B10 3773/4885NOS3 4262/4885 |
| US-12492194-B2 | HPK1 inhibitors | PGK1, PCK1, PDXK | KDM4E 2851/4885HSD17B10 1201/4885NOS3 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.